1. 607 Impact of anifrolumab on neuropsychiatric manifestations of depression and suicidality in patients with systemic lupus erythematosus. (14th December 2022) Authors: Manzi, Susan; Lindholm, Catharina; Hupka, Ihor; Shroff, Manish; Abreu, Gabriel; Werther, Shanti; Tummala, Raj Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 3 Page Start: A32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Issue 2 (11th November 2022) Authors: Kalunian, Kenneth C.; Furie, Richard; Morand, Eric F.; Bruce, Ian N.; Manzi, Susan; Tanaka, Yoshiya; Winthrop, Kevin; Hupka, Ihor; Zhang, Lijin (Jinny); Werther, Shanti; Abreu, Gabriel; Hultquist, Micki; Tummala, Raj; Lindholm, Catharina; Al‐Mossawi, Hussein Journal: Arthritis & rheumatology Issue: Volume 75:Issue 2(2023) Page Start: 253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Issue 7 (25th March 2022) Authors: Vital, Edward M; Merrill, Joan T; Morand, Eric F; Furie, Richard A; Bruce, Ian N; Tanaka, Yoshiya; Manzi, Susan; Kalunian, Kenneth C; Kalyani, Rubana N; Streicher, Katie; Abreu, Gabriel; Tummala, Raj Journal: Annals of the rheumatic diseases Issue: Volume 81:Issue 7(2022) Page Start: 951 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. (July 2021) Authors: Furie, Richard; Morand, Eric F; Askanase, Anca D; Vital, Edward M; Merrill, Joan T; Kalyani, Rubana N; Abreu, Gabriel; Pineda, Lilia; Tummala, Raj Journal: Lupus Issue: Volume 30:Number 8(2021) Page Start: 1254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials. (11th March 2022) Authors: Stull, Donald; O'Quinn, Sean; Williams, Betsy; Bean, Stephanie; Schwetje, Erik; Abreu, Gabriel; Tummala, Raj Journal: Rheumatology Issue: Volume 61:Number 12(2022) Page Start: 4731 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. (March 2022) Authors: Strand, Vibeke; O'Quinn, Sean; Furie, Richard A; Morand, Eric F; Kalunian, Kenneth C; Schwetje, Erik G; Abreu, Gabriel; Tummala, Raj Journal: Lancet Issue: Volume 4:Number 3(2022) Page Start: e198 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study. Issue 5 (24th March 2021) Authors: Chatham, W. Winn; Furie, Richard; Saxena, Amit; Brohawn, Philip; Schwetje, Erik; Abreu, Gabriel; Tummala, Raj Journal: Arthritis & rheumatology Issue: Volume 73:Issue 5(2021) Page Start: 816 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Issue 5 (23rd January 2023) Authors: Morand, Eric F; Abreu, Gabriel; Furie, Richard A; Golder, Vera; Tummala, Raj Journal: Annals of the rheumatic diseases Issue: Volume 82:Issue 5(2023) Page Start: 639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. O24 Flare assessments in patients with active systemic lupus erythematosus (SLE) treated with anifrolumab in 2 phase 3 trials. (23rd March 2020) Authors: Furie, Richard; Morand, Eric F; Askanase, Anca; Vital, Ed; Kalyani, Rubana N; Abreu, Gabriel; Pineda, Lilia; Tummala, Raj Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 1 Page Start: A19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. O25 Efficacy of anifrolumab in active systemic lupus erythematosus (SLE): patient subgroup analysis of BICLA response in 2 phase 3 trials. (23rd March 2020) Authors: Morand, Eric F; Furie, Richard; Tanaka, Yoshiya; Kalyani, Rubana N; Abreu, Gabriel; Pineda, Lilia; Tummala, Raj Journal: Lupus science & medicine Issue: Volume 7(2020)Supplement 1 Page Start: A20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗